These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

658 related items for PubMed ID: 25172158

  • 1. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
    Parise C, Caggiano V.
    Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
    [Abstract] [Full Text] [Related]

  • 2. Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype.
    Parise C, Caggiano V.
    J Breast Cancer; 2016 Jun; 19(2):112-21. PubMed ID: 27382386
    [Abstract] [Full Text] [Related]

  • 3. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes.
    Parise CA, Caggiano V.
    Cancer Causes Control; 2019 May; 30(5):417-424. PubMed ID: 30879205
    [Abstract] [Full Text] [Related]

  • 4. Variation in breast cancer subtypes with age and race/ethnicity.
    Parise CA, Bauer KR, Caggiano V.
    Crit Rev Oncol Hematol; 2010 Oct; 76(1):44-52. PubMed ID: 19800812
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
    Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA.
    J Natl Cancer Inst; 2014 Apr 28; 106(5):. PubMed ID: 24777111
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
    Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, Lacey JV.
    J Natl Cancer Inst; 2012 Jul 18; 104(14):1094-101. PubMed ID: 22773826
    [Abstract] [Full Text] [Related]

  • 11. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
    Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V.
    Cancer; 2008 Feb 15; 112(4):737-47. PubMed ID: 18189290
    [Abstract] [Full Text] [Related]

  • 12. Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010.
    Parise CA, Caggiano V.
    BMC Cancer; 2013 Oct 02; 13():449. PubMed ID: 24083624
    [Abstract] [Full Text] [Related]

  • 13. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups.
    Kurian AW, Fish K, Shema SJ, Clarke CA.
    Breast Cancer Res; 2010 Oct 02; 12(6):R99. PubMed ID: 21092082
    [Abstract] [Full Text] [Related]

  • 14. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
    Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V.
    Cancer; 2007 May 01; 109(9):1721-8. PubMed ID: 17387718
    [Abstract] [Full Text] [Related]

  • 15. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, Spirtas R, Burkman RT, Strom BL, McDonald JA, Folger SG, Simon MS, Sullivan-Halley J, Press MF, Bernstein L.
    BMC Cancer; 2013 May 04; 13():225. PubMed ID: 23642215
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Relationship of established risk factors with breast cancer subtypes.
    McCarthy AM, Friebel-Klingner T, Ehsan S, He W, Welch M, Chen J, Kontos D, Domchek SM, Conant EF, Semine A, Hughes K, Bardia A, Lehman C, Armstrong K.
    Cancer Med; 2021 Sep 04; 10(18):6456-6467. PubMed ID: 34464510
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.